7AL0
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Finland and Sweden. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, develo… Read more
7AL0 (7AL0) - Total Liabilities
Latest total liabilities as of June 2025: €120.96 Million EUR
Based on the latest financial reports, 7AL0 (7AL0) has total liabilities worth €120.96 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
7AL0 - Total Liabilities Trend (2021–2024)
This chart illustrates how 7AL0's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
7AL0 Competitors by Total Liabilities
The table below lists competitors of 7AL0 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Insig Ai PLC
LSE:INSG
|
UK | GBX2.05 Million |
|
ACCURAY (XEJ.SG)
STU:XEJ
|
Germany | €423.54 Million |
|
ROMIOS GOLD RES
MU:D4R
|
Germany | €1.25 Million |
|
PRI HEALTH CARE (PGZ.SG)
STU:PGZ
|
Germany | €1.94 Billion |
|
UNITED CO.RUSAL DL -01
MU:R6L
|
Germany | €10.45 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down 7AL0's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 7AL0's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 7AL0 (2021–2024)
The table below shows the annual total liabilities of 7AL0 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €234.93 Million | +120.39% |
| 2023-12-31 | €106.59 Million | +32.36% |
| 2022-12-31 | €80.53 Million | +58.13% |
| 2021-12-31 | €50.93 Million | -- |